A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers

Liu, Ke Jun; Guan, Zhong; Liang, Yaping; Yang, Xu; Peng, Jinrong; Huang, He; Shao, Qing; Wang, Meng Zhao; Zhu, Yibing; Wu, Chang; Wang, Shao-Bin; Xiong, Jian; Bai, Yu; Yu, Shufei; Zhang, Yang; Hu, Xiao; Feng, J.; Wu, Shixiu; Jiao, Shun Chang; Zhou, C.; Wang, Jie; Wu, Haoming

doi:10.5114/aoms.2014.44862

Cited by 11 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accounting for >80% of primary lung cancers, non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related mortality all around the world [ 1 ]. Patients with advanced non-squamous NSCLC have especially poor prognosis, with only 4–6 months median progression-free survival (PFS) and 8–10 months median overall survival (OS) [ 2 , 3 ]. For this group of patients, NCCN guidelines recommend bevacizumab plus chemotherapy as the preferred first-line treatment option and bevacizumab with pemetrexed as the standard maintenance treatment strategy.…”

Section: Introductionmentioning

confidence: 99%

Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed

et al. 2017

View full text Add to dashboard Cite

In this retrospective study, we investigated whether the kinetic change of serum carcinoembryonic antigen (CEA) levels can be an early indicator for the progression in metastatic non-small cell lung cancer (NSCLC) patients during maintenance therapy with bevacizumab plus pemetrexed. Ten patients diagnosed with metastatic lung adenocarcinoma who received a first-line therapy including bevacizumab-based chemotherapy and a following maintenance therapy including bevacizumab plus pemetrexed from June 2015 to October 2016 were recruited in this study. During the maintenance treatment, patients’ CEA levels all elevated at or after the first cycle of maintenance treatment with a median CEA elevation-free survival time as 17.7 days, which was far more shorter than the median progression-free survival time evaluated by CT imaging specially for maintenance treatment (102.2 days). Before the disease progressed, the values of CEA increased steadily for several cycles with the response evaluation still as stable disease, indicating that the changes of CEA level would be earlier and more sensitive for detection of progression. The CEA kinetic was calculated with a mean of 9.6451 and a median of 8.0135, which sensitively reflected the increasing rate of CEA levels at an early stage. Our study showed that the kinetic change of CEA could be an early predictor for the progression in metastatic NSCLC patients during maintenance therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Surgery is a first-line treatment. The role of pre-operative and adjuvant chemotherapy is not well established [18–21]. Patients usually present with non-specific symptoms.…”

Section: Discussionmentioning

confidence: 99%

Klotho expression and nodal involvement as predictive factors for large cell lung carcinoma

Bromińska

Gabryel

Jarmołowska-Jurczyszyn

et al. 2019

aoms

View full text Add to dashboard Cite

Introduction Klotho has been recently described as a carcinogenesis suppressor. Large cell neuroendocrine lung carcinoma (LCNEC) is a rare, highly malignant neoplasm. In the light of increasing incidence of neuroendocrine tumours, biomarkers predicting survival are needed. We consider that Klotho might be one. Material and methods We analysed records of all patients diagnosed with LCNEC, atypical carcinoid and typical carcinoid operated on in our institution between 2007 and 2015. Initially, we found 134 cases. Forty-six specimens were unattainable and thus excluded from research. All patients diagnosed with LCNEC according to the WHO classification were included in the study. Immunohistochemical staining for Klotho was performed. We retrospectively reviewed patient charts and analysed multiple variables. Results Positive staining for Klotho was present in 36 tissue specimens, while 12 patients were Klotho-negative. Survival length was significantly higher in Klotho-positive cases ( p = 0.024), while advanced nodal status (N1 and N2) represented a marker of poor outcome ( p = 0.011). In multivariate analysis, both Klotho presence ( p = 0.015; HR = 0.37; 95% CI: 0.17–0.86) and nodal involvement ( p = 0.007; HR = 3.04; 95% CI: 1.37–6.82) were independent prognostic factors. Tumour vessel invasion and visceral pleura infiltration were not associated with worse treatment results. Klotho presence predicted a favourable prognosis in these groups ( p = 0.018; p = 0.007). Conclusions Our results suggest that Klotho might be a positive factor for predicting survival in LCNEC and nodal involvement a negative one. Thus, these two markers may assist in the selection of subjects with unfavourable prognosis and to personalise therapy regimens.

show abstract

“…DCP for intravesical injection was developed for a Chinese phase I human clinical trial completed in 2006. From 2007 to 2009 a double-blind, randomized multicenter phase II clinical trial comparing dicycloplatin and paclitaxel to carboplatin and paclitaxel in non-small cell lung cancer was completed (NSCLC) [7,8]. Two hundred and forty chemotherapy-naïve patients with advanced NSCLC were recruited from 15 multi-center/hospitals in China.…”

Section: Introductionmentioning

confidence: 99%

The first American cancer patient to receive dicycloplatin chemotherapy: A case report

Yu¹,

Mw²,

Jiao³

et al. 2017

J Cancer Res Ther.

View full text Add to dashboard Cite

Dicycloplatin (DCP), an effective platinum drug, was developed in China and approved by Chinese FDA in 2012. Its side effects are more bearable than those of cisplatin and carboplatin. The bladder cancer patient presented here was a 65-year-old Caucasian American male diagnosed at West Virginia University (WVU) Hospital in the USA and received 8 weeks of dicycloplatin chemotherapy in Beijing in 2016. He experienced moderate fatigue and aches but no vomiting or hair loss. His blood values decreased but remained in normal range. Quarterly cystoscopic follow-ups at WVU Hospital found no tumor recurrence. Studies of dicycloplatin-induced activation of the molecular signaling pathway in response to DNA damage, including investigation of Chk2, BRCA1 and p53, demonstrated that the signaling pathway is activated only in cancer cells, not in normal cells. Other in vitro data also indicate DCP mainly affects tumor cells, largely bypassing normal cells. These findings may explain DCP's more bearable side effects. Dicycloplatin may offer chemotherapeutic advantages over some platinum drugs in cancer treatment.

show abstract

A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers

Cited by 11 publications

References 26 publications

Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed

Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed

Klotho expression and nodal involvement as predictive factors for large cell lung carcinoma

The first American cancer patient to receive dicycloplatin chemotherapy: A case report

Contact Info

Product

Resources

About